Healthcare / Pharmaceutical RetailersShenzhen
$11.70
-0.22 (-1.85%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $1.5B · quality 79.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.9B
P/E
24.4x
↑EV/EBITDA
3.9x
↓ROE
3.6%
↑Gross Margin
32.6%
↓Debt/Equity
0.36
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-0.2%
FCF CAGR
-14.2%
FCF margin
7.8%
FCF / Net income
5.14x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $17.34B · net income $263.4M · FCF $1.36B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $17.34B | $17.34B | $18.00B | $17.38B | $17.43B |
| Net Income | $263.4M | $263.4M | $114.1M | $549.4M | $1.01B |
| EBITDA | $1.79B | $1.79B | $1.61B | $2.00B | $2.38B |
| EPS | 0.46 | 0.46 | 0.19 | 0.92 | 1.70 |
| Gross Margin | 32.6% | 32.6% | 31.8% | 33.0% | 35.0% |
| Operating Margin | 4.3% | 4.3% | 3.2% | 6.1% | 9.3% |
| Net Margin | 1.5% | 1.5% | 0.6% | 3.2% | 5.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.36 | 0.36 | 0.40 | 0.39 | 0.42 |
| Current Ratio | 1.34 | 1.34 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.36B | $1.36B | $1.47B | $1.86B | $2.15B |
| Returns | |||||
| ROE | 3.6% | 3.6% | 1.5% | 7.1% | 13.6% |
| Valuation | |||||
| P/E | 24.38 | 24.38 | 63.88 | 25.36 | 19.39 |
| EV/EBITDA | 3.95 | 3.95 | 4.28 | 6.64 | 8.04 |
| P/B | 0.92 | 0.92 | 0.97 | 1.80 | 2.64 |
| Growth & Yield | |||||
| Revenue Growth | -3.7% | -3.7% | 3.6% | -0.3% | — |
| EPS Growth | 137.2% | 137.2% | -79.1% | -45.7% | — |
| Dividend Yield | 5.9% | 5.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
31.4%
EPS terminal req.
$1.04
Spread vs growth
105.8%
5Y implied EPS CAGR
22.4%
EPS terminal req.
$1.26
Spread vs growth
114.8%
10Y implied EPS CAGR
16.0%
EPS terminal req.
$2.02
Spread vs growth
121.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-19.3%
Start / end P/E
81.1x → 25.6x
EPS bridge
0.19 → 0.46
Residual
-93.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.